Selective Reversible Inhibition of Liver Carnitine Palmitoyl-Transferase 1 by Teglicar Reduces Gluconeogenesis and Improves Glucose Homeostasis
Open accessThe DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We have developed a new antihyperglycemic agent (teglicar) through the selective and reversible inhibition of the liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1). RESEARCH DESIGN AND METHODS: Glucose production was investigated in isolated hepatocytes and during pancreatic clamps in healthy rats. Chronic treatments on C57BL/6J, db/db, high-fat fed mice, and rats were performed to understand glucose metabolism and insulin sensitivity. RESULTS: In isolated hepatocytes, teglicar concentration dependently reduced ketone bodies and glucose production up to 72 and 50%, respectively. In rats, teglicar reduced the endogenous glucose production (−62%) without affecting peripheral glucose utilization. Heart 2-[3H]deoxyglucose uptake in mice was also not affected, confirming in vivo the drug selectivity toward L-CPT1. Chronic treatment in db/db mice (50 mg/kg/bid; 45 days) reduced postabsorptive glycemia (−38%), water consumption (−31%), and fructosamine (−30%). Such antidiabetic activity was associated with an improved insulin sensitivity assessed by the insulin tolerance test. A significant 50% increase in hepatic triglyceride content (HTGC) was found, although plasma alanineaminotransferase was not altered. In addition, long-term teglicar administration to high-fat fed C57BL/6J mice normalized glycemia (−19%) and insulinemia (−53%). Long-term teglicar administration (30 days, 80 mg/kg) in healthy overnight-fasted rats slightly reduced basal glycemia (−20%, ns), reduced basal insulin levels by 60%, doubled triglycerides, and increased free-fatty acids (+53%). HTGC was markedly increased, but liver and peripheral insulin sensitivity assessed by hyperinsulinemiceuglycemic clamp were not affected. CONCLUSIONS: Teglicar, in vitro and in animal models, reduces gluconeogenesis and improves glucose homeostasis, refreshing the interest in selective and reversible L-CPT1 inhibition as a potential antihyperglycemic approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![FIG. 2. A: Pancreatic clamp procedure involves the infusion of 0.4 μCi/min [3-3H]glucose, 1.5 μg/kg/min somatostatin, and 0.7 mU/kg/min insulin. Control rats received saline throughout the experiment, whereas teglicar infusion was started at 120'. Rats receiving the drug also received glucose to prevent hypoglycemia. B: Representation of teglicar-induced drop in glycemia during pancreatic clamp. Euglycemia is restored by glucose coinfusion. C: Rates of glucose production before (EGP1) and during (EGP2) the infusion of teglicar (white bars) or saline (black bars) in postabsorptive SD rats. The box plots indicate the mean ± SE from five different pancreatic clamps/group. *P < 0.05 vs. saline.](https://figures.cochat.ai/paper-figures/8875472cd4674a46820fea716db102b5/selective-reversible-inhibition-of-liver-carnitine-palmitoyl-transferase-1-by-figure-2.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Similar conclusions were reached by two meta-analyses that included these and other studies129,130.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [129]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Randle, P. J., Garland, P. B., Hales, C. N., & Newsholme, E. A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91500-9 · Cited by 5,093 · cited 1×
“In fact, an increase of peripheral GU would be indicative of an ongoing reversed Randle effect (28,29) through inhibition of MCPT1.”
BackgroundPathogenesis of NIDDM. A balanced overview.
DeFronzo, R. A., Bonadonna, R. C., & Ferrannini, E. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.318 · Cited by 2,085
The Mitochondrial Carnitine Palmitoyltransferase System — From Concept to Molecular Analysis
McGarry, J. D., & Brown, N. F. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00001.x · Cited by 1,616 · cited 1×
“CPT1 (12) is a ubiquitous enzyme that plays a pivotal role in mitochondrial fatty acid b-oxidation.”
BackgroundForetz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181 · cited 1×
“The recent discovery (42) that metformin reduces hepatic gluconeogenesis independently of the LKB1/AMPK pathway, which, instead, blunts metformin efficacy, opens up the possibility of an advantageous association with L-CPT1 inhibitors.”
BackgroundReduced Food Intake and Body Weight in Mice Treated with Fatty Acid Synthase Inhibitors
Loftus, T. M., Jaworsky, D. E., Frehywot, G. L., Townsend, C. A., Ronnett, G. V., Lane, M. D., & Kuhajda, F. P. (2000) · Science · doi:10.1126/science.288.5475.2379 · Cited by 1,004
STANLEY, J. C. (1981) · British Journal of Anaesthesia · doi:10.1093/bja/53.2.123 · Cited by 731
Obici, S., Feng, Z., Arduini, A., Conti, R., & Rossetti, L. (2003) · Nature Medicine · doi:10.1038/nm873 · Cited by 548
Self-citationDose-response curves for in vivo insulin sensitivity in individual tissues in rats
Kraegen, E. W., James, D. E., Jenkins, A. B., & Chisholm, D. J. (1985) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1985.248.3.e353 · Cited by 408
[19] Assay of peroxisomal β-oxidation of fatty acids
Lazarow, P. B. (1981) · Methods in Enzymology · doi:10.1016/s0076-6879(81)72021-4 · Cited by 367
Dobbins, R. L., Szczepaniak, L. S., Bentley, B., Esser, V., Myhill, J., & McGarry, J. D. (2001) · Diabetes · doi:10.2337/diabetes.50.1.123 · Cited by 315 · cited 2×
“Etomoxir, a CPT1 inhibitor with hypoglycemic activity in diabetic patients, was abandoned because of its inability to distinguish between the liver (L-CPT1) and the muscle (M-CPT1) isoform of CPT1, causing undesirable cardiac effects (16) and, possibly, muscle insulin resistance (17).”
Background
Research works printed but not linked: 1
- Walter, 1976, Pyruvate carboxylase: intracellular localization and regulation, 239
Cited by
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
The interaction of hepatic lipid and glucose metabolism in liver diseases
Bechmann, L. P., Hannivoort, R. A., Gerken, G., Hotamisligil, G. S., Trauner, M., & Canbay, A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.08.025 · Cited by 994
CPT1A-mediated Fat Oxidation, Mechanisms, and Therapeutic Potential
Schlaepfer, I. R., & Joshi, M. (2020) · Endocrinology · doi:10.1210/endocr/bqz046 · Cited by 732
Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer
Qu, Q., Zeng, F., Liu, X., Wang, Q. J., & Deng, F. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.132 · Cited by 545
CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis
Wang, Y.-N., Zeng, Z.-L., Lu, J., Wang, Y., Liu, Z.-X., He, M.-M., Zhao, Q., Wang, Z.-X., Li, T., Lu, Y.-X., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0384-z · Cited by 380
Mitochondrial fatty acid oxidation in obesity
Serra, D., Mera, P., Malandrino, M. I., Mir, J. F., & Herrero, L. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4875 · Cited by 246
“Alternatively, it has been reported that the admistration of CPT1 inhibitors reduces gluconeogenesis and improves glucose homeostasis, although chronic treatments on HFD-treated mice caused hepatic steatosis (28, 53).”
Gusdon, A. M., Song, K.-X., & Qu, S. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/637027 · Cited by 168
Mitochondrial CPT1A: Insights into structure, function, and basis for drug development
Liang, K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1160440 · Cited by 156
“Compared to etomoxir, ST1326 (oral formulation-Teglicar) is more selective for CPT1A while CPT1B can also be inhibited by etomoxir (Conti et al., 2011).”
BackgroundInfluentialDissociating fatty liver and diabetes
Sun, Z., & Lazar, M. A. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.09.005 · Cited by 136
Impaired mitochondrial fat oxidation induces adaptive remodeling of muscle metabolism
Wicks, S. E., Vandanmagsar, B., Haynie, K. R., Fuller, S. E., Warfel, J. D., Stephens, J. M., Wang, M., Han, X., Zhang, J., Noland, R. C., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418560112 · Cited by 131
“(22) using the liver-specific Cpt1 inhibitor, teglicar, it is clearly important to understand the detailed mechanisms underlying the impact of tissue-specific and isoform-selective Cpt1 inhibition to develop therapeutic inhibitors with maximum metabolic benefits and minimal side effects.”
BackgroundCarnitine Inborn Errors of Metabolism
Almannai, M., Alfadhel, M., & El‐Hattab, A. W. (2019) · Molecules · doi:10.3390/molecules24183251 · Cited by 150
Triglyceride cycling enables modification of stored fatty acids
Wunderling, K., Zurkovic, J., Zink, F., Kuerschner, L., & Thiele, C. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00769-z · Cited by 117
The Metabolic Landscape of Prostate Cancer
Giunchi, F., Fiorentino, M., & Loda, M. F. (2018) · European Urology Oncology · doi:10.1016/j.euo.2018.06.010 · Cited by 123
Altered mitochondrial metabolism in the insulin‐resistant heart
Makrecka‐Kuka, M., Liepinsh, E., Murray, A. J., Lemieux, H., Dambrova, M., Tepp, K., Puurand, M., Käämbre, T., Han, W. H., de Goede, P., et al. (2019) · Acta Physiologica · doi:10.1111/apha.13430 · Cited by 102
Norton, L., Fourcaudot, M. J., Abdul-Ghani, M. A., Winnier, D. A., Mehta, F. F., Jenkinson, C. P., & DeFronzo, R. A. (2011) · Diabetologia · doi:10.1007/s00125-011-2289-z · Cited by 94
Soto-Gutierrez, A., Gough, A., Vernetti, L. A., Taylor, D., & Monga, S. P. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217707731 · Cited by 92
Oliynyk, G., Ruiz-Pérez, M. V., Sainero‐Alcolado, L., Dzieran, J., Zirath, H., Gallart‐Ayala, H., Wheelock, C. E., Johansson, H. J., Nilsson, R., Lehtiö, J., et al. (2019) · iScience · doi:10.1016/j.isci.2019.10.020 · Cited by 98
Use of dicarboxylic acids in type 2 diabetes
Mingrone, G., Castagneto‐Gissey, L., & Macé, K. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04177.x · Cited by 82
Glucose challenge metabolomics implicates medium-chain acylcarnitines in insulin resistance
Nowak, C., Hetty, S., Salihović, S., Castillejo-López, C., Ganna, A., Cook, N. L., Broeckling, C. D., Prenni, J. E., Shen, X., Giedraitis, V., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26701-0 · Cited by 73
Hepatic CPT1A Facilitates Liver–Adipose Cross Talk via Induction of FGF21 in Mice
Sun, W., Nie, T., Li, K., Wu, W., Long, Q., Feng, T., Mao, L., Gao, Y. Z., Liu, Q., Gao, X., et al. (2021) · Diabetes · doi:10.2337/db21-0363 · Cited by 73
The role and therapeutic implication of CPTs in fatty acid oxidation and cancers progression.
Wang, J., Xiang, H., Lu, Y., Wu, T., & Ji, G. (2021) · American Journal of Cancer Research · Cited by 68
The Physiological and Pathological Role of Acyl-CoA Oxidation
Szrok-Jurga, S., Czumaj, A., Turyn, J., Hebanowska, A., Świerczyński, J., Śledziński, T., & Stelmańska, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914857 · Cited by 62
Hepatic ATGL knockdown uncouples glucose intolerance from liver TAG accumulation
Ong, K. T., Mashek, M. T., Bu, S. Y., & Mashek, D. G. (2012) · The FASEB Journal · doi:10.1096/fj.12-213454 · Cited by 54
Mozolewska, P., Duzowska, K., Pakiet, A., Mika, A., & Śledziński, T. (2020) · Anticancer Research · doi:10.21873/anticanres.14487 · Cited by 57
Legumes as Functional Food for Cardiovascular Disease
Angeles, J. G. C., Villanueva, J. C., Uy, L. Y., Mercado, S. M. Q., Tsuchiya, M. C., Lado, J. P., Angelia, M. R. N., Bercansil, M. C. M. L., Estacio, M. A. C., & Torio, M. A. O. (2021) · Applied Sciences · doi:10.3390/app11125475 · Cited by 55
Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development
Mittermayer, F., Caveney, E., De Oliveira, C., Gourgiotis, L., Puri, M., Tai, L.-J., & Turner, J. R. (2015) · Current Diabetes Reviews · doi:10.2174/1573399810666141224121927 · Cited by 47
Emerging roles of fatty acid metabolism in cancer and their targeted drug development
An, Q., Lin, R., Wang, D., & Wang, C. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114613 · Cited by 47
Onodera, T., Wang, M.-Y., Rutkowski, J. M., Deja, S., Chen, S., Balzer, M. S., Kim, D.-S., Sun, X., An, Y., Field, B. C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42188-4 · Cited by 45
Gugiatti, E., Tenca, C., Ravera, S., Fabbi, M., Ghiotto, F., Mazzarello, A. N., Bagnara, D., Reverberi, D., Zarcone, D., Cutrona, G., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.175414 · Cited by 41
Carnitine Palmitoyltransferase 1b Deficiency Protects Mice from Diet-Induced Insulin Resistance
Yang, Q. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000361 · Cited by 48
Progress of potential drugs targeted in lipid metabolism research
Liang, K., & Dai, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1067652 · Cited by 38
Hu, W., Jiang, C., Kim, M., Yang, W., Zhu, K., Guan, D., Lv, W., Xiao, Y., Wilson, J. R., Rader, D. J., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.06.004 · Cited by 42
Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?
Majumdar, S. K., & Inzucchi, S. E. (2013) · Endocrine · doi:10.1007/s12020-013-9884-3 · Cited by 39
Raasch, M., Fritsche, E., Kurtz, A., Bauer, M., & Mosig, A. S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.008 · Cited by 29
Fuller, S. E., Huang, T., Simon, J., Batdorf, H. M., Essajee, N. M., Scott, M. C., Waskom, C., Brown, J. M., Burke, S. J., Collier, J. J., et al. (2019) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00820.2018 · Cited by 33
Zhao, S., Wang, D., Li, Y., Han, L., Xiao, X., Ma, M., Wan, D. C., An, H., & Ma, Y. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s130566 · Cited by 28
Shokouh, P., Jeppesen, P. B., Christiansen, C., Mellbye, F. B., Hermansen, K., & Gregersen, S. (2019) · Nutrients · doi:10.3390/nu11092074 · Cited by 31
Small Molecule Inhibitors of Metabolic Enzymes Repurposed as a New Class of Anthelmintics
Tyagi, R., Maddirala, A. R., Elfawal, M. A., Fischer, C., Bulman, C. A., Rosa, B. A., Gao, X., Chugani, R., Zhou, M., Helander, J., et al. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00090 · Cited by 27
Targeting leukemia’s “fatty tooth”
Samudio, I. J., & Konopleva, M. Y. (2015) · Blood · doi:10.1182/blood-2015-08-665125 · Cited by 27
Singh, S. B., Kang, L., Nawrocki, A. R., Zhou, D., Wu, M. S., Previs, S. F., Miller, C., Liu, H., Hines, C. D. G., Madeira, M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164133 · Cited by 23
Metabolic Pathway Inhibition in Liver Cancer
Zarrinpar, A. (2017) · SLAS TECHNOLOGY · doi:10.1177/2472630317698683 · Cited by 23
Metabolic signatures of insulin resistance in non-diabetic individuals
Arjmand, B., Fana, S. E., Ghasemi, E., Kazemi, A. S., Ghodssi-Ghassemabadi, R., Dehghanbanadaki, H., Najjar, N., Kakaei, A., Forouzanfar, K., Nasli‐Esfahani, E., et al. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01130-3 · Cited by 25
Hepatic Mediators of Lipid Metabolism and Ketogenesis: Focus on Fatty Liver and Diabetes
Fernandes, G. W., & Bocco, B. M. L. C. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816999201103141216 · Cited by 20
Hepatic Glucocorticoid Receptor Action and Glucose Homeostasis
Chang, M., & Wang, J.-C. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf030 · Cited by 21
Targeting lipid metabolism in cancer: neuroblastoma
Agostini, M., Melino, G., Habeb, B. F., Calandria, J. M., & Bazan, N. G. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10040-8 · Cited by 21
Modulators for palmitoylation of proteins and small molecules
Fan, Z., Hao, Y., Huo, Y., Cao, F., Li, L., Xu, J., Song, Y., & Yang, K. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116408 · Cited by 19
Paraiso, W. K. D., García-Chica, J., Ariza, X., Zagmutt, S., Fukushima, S., García, J., Mochida, Y., Serra, D., Herrero, L., Kinoh, H., et al. (2021) · Biomaterials Science · doi:10.1039/d1bm00689d · Cited by 18
Role of the Adipocyte in Development of Type 2 Diabetes
Croniger, C. (2011) · InTech eBooks · doi:10.5772/1543 · Cited by 19
Lin, H., Wang, L., Chen, H., Shen, Y., Wang, C., Xue, Y., Zheng, Z., Zhang, Y., Xia, D., Wu, Y., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.03.026 · Cited by 18
Fibroblast Growth Factor 21-Null Mice Do Not Exhibit an Impaired Response to Fasting
Antonellis, P. J., Hayes, M. P., & Adams, A. C. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2016.00077 · Cited by 18
Wunderling, K., Leopold, C., Jamitzky, I., Yaghmour, M. H., Zink, F., Kratky, D., & Thiele, C. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101150 · Cited by 17
Wong, T. L., Kong, Y., & Ma, S. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000837 · Cited by 19
Chen, H., Yang, Z., Sun, Y., Yin, S., Tang, M., & Zhang, F. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2703095 · Cited by 19
Lipid metabolism: a molecular switch to control inflammation
Cheng, S., Xie, L., Wu, J., & Yang, F. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116294 · Cited by 15
Ma, Y., Fang, S., Zhao, S., Wang, X., Wang, D., Ma, M., Luo, T., & An, H. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.01.064 · Cited by 13
A mini review of small-molecule inhibitors targeting palmitoyltransferases
Hu, X., Zhu, X., Yu, W., Zhang, Y., Yang, K., Liu, Z., Qiao, X., & Song, Y. (2022) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2022.100041 · Cited by 12
Sun, J., Liu, J., Chen, F., Wang, X., & Wu, G. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2445774 · Cited by 16
Screening of CPT1A-Targeting Lipid Metabolism Modulators Using Mitochondrial Membrane Chromatography
Su, W., Xu, F., Zhong, J., Hu, R., Wang, L., Li, H., Yang, Z., Ge, S., He, H., Han, S., et al. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c18102 · Cited by 14
The Regulation of Energy Metabolism Pathways Through L-Carnitine Homeostasis
Liepinsh, E., Kalvinsh, I., & Dambrov, M. (2011) · InTech eBooks · doi:10.5772/22478 · Cited by 12
Response of Liver Metabolic Pathways to Ketogenic Diet and Exercise Are Not Additive
Huang, T.-Y., Goldsmith, F., Fuller, S. E., Simon, J., Batdorf, H. M., Scott, M. C., Essajee, N. M., BROWN, J. M., Burk, D. H., Morrison, C. D., et al. (2019) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002105 · Cited by 12
Dysfunction of the carnitine cycle in tumor progression
Wang, X., Yang, C., Huang, C., & Wang, W. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35961 · Cited by 11
Fatty acid metabolism: A new target for nasopharyngeal carcinoma therapy
Li, J., Ping, P., Li, Y., & Xu, X. (2024) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2024.06.05 · Cited by 16
Obici, S., Tavoni, T. M., Barrena, H. C., Curi, R., & Bazotte, R. B. (2012) · Cell Biochemistry and Function · doi:10.1002/cbf.2809 · Cited by 11
Kim, M., So, J., & Shin, D. (2023) · Scientific Reports · doi:10.1038/s41598-023-44935-5 · Cited by 12
The Role of the CPT Family in Cancer: Searching for New Therapeutic Strategies
Duan, Y., Liu, J., Li, A., Liu, C. X., Shu, G., & Yin, G. (2024) · Biology · doi:10.3390/biology13110892 · Cited by 14
Kuerschner, L., Leyendecker, P., Klizaite, K., Fiedler, M., Saam, J., & Thiele, C. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100188 · Cited by 9
Cacciola, N. A., Sepe, F., Fioriniello, S., Petillo, O., Margarucci, S., Scivicco, M., Peluso, G., Balestrieri, A., Bifulco, G., Restucci, B., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16070987 · Cited by 8
Etomoxir: an old dog with new tricks
McGuffee, R. M., Mccommis, K., & Ford, D. A. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100604 · Cited by 6
Yang, S., Liu, Y., Tang, C., Han, A., Lin, Z., Quan, J., & Yang, Y. (2023) · iScience · doi:10.1016/j.isci.2023.107869 · Cited by 7
Wang, G., Yuan, H.-J., Kong, Q.-Q., Zhang, J., Xiao, H., Gong, S., Xu, M., He, N., Luo, M., & Tan, J. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166921 · Cited by 6
Tassoni, E., Conti, R., Gallo, G., Vincenti, S., Mastrofrancesco, L., Brunetti, T., Cabri, W., & Giannessi, F. (2011) · ChemMedChem · doi:10.1002/cmdc.201100289 · Cited by 3
Self-citationLok, A. S.-F. (2011) · Hepatology · doi:10.1002/hep.24520 · Cited by 3
Direct Expression of CPT1a Enables a High Throughput Platform for the Discovery of CPT1a Modulators
Chen, J., Tran, T., Wong, A., Wang, L., Annaluru, P., Sreekanth, V., Murthy, S., Munjeti, L., Park, T., Bhat, U., et al. (2025) · Applied Biosciences · doi:10.3390/applbiosci4020025 · Cited by 2
Chiodi, P. (2017) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2016.13.555563 · Cited by 2
Zhang, R., Nie, D., Chen, Y., Zeng, Y., Huang, Y., & Xiao, N. (2020) · Iranian Journal of Science and Technology Transactions A Science · doi:10.1007/s40995-020-00940-1 · Cited by 1
Effect of Direct-Acting Antivirals on Lipid and Glucose Metabolism in Chronic HCV Patients
Kamal, E., El-Sayed, A., & Mohammed, M. (2019) · Minia Journal of Medical Research · doi:10.21608/mjmr.2022.221908 · Cited by 1
Ong, K. T. (2013) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 2
Arduini, A., & Bonomini, M. (2011) · Hepatology · doi:10.1002/hep.24348 · Cited by 2
Self-citationMalandrino, M. I. (2013) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Hepatic Mitochondrial Fatty Acid Oxidation and Type 2 Diabetes
Mansouri, A., Langhans, W., Girard, J. R., & Prip‐Buus, C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801585-8.00028-2
Roles of PI3-kinase and ARAP2 in regulating glucose metabolism
Chaudhari, A. (2016) · Gothenburg University Publications Electronic Archive (Gothenburg University)
La reprogrammation métabolique des carcinomes hépatocellulaires β-caténine mutés
Senni, N., Savall, M., & Bossard, P. (2018) · médecine/sciences · doi:10.1051/medsci/2018285
Development of avocado derived polyhydroxylated fatty alcohols as metabolic modulators
Ahmed, N. (2019) · The Atrium (University of Guelph)
Coordinate control of metabolic flux with liver energy status by AMPK in vivo
Hasenour, C. M. (2014)
Descifrando las funciones de la microbiota intestinal en la obesidad.
López‐Almela, I. (2021) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/174897
Orellana‐Gavaldà, J. M., Herrero, L., Malandrino, M. I., Asins, G., Hegardt, F. G., & Serra, D. (2011) · Hepatology · doi:10.1002/hep.24373
Zhang, L., Junco, M., Townsend, D. M., & Maldonado, E. N. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.06.002 · Cited by 1
Design and synthetic evaluation of novel andrographolide and etomoxir-based CPT1 Inhibitors
Daggubati, S. (2025) · Magna Scientia Advanced Biology and Pharmacy · doi:10.30574/msabp.2025.16.1.0062
Chen, Q., Li, C., Wu, L., Wang, Y., Liu, H., Zhang, Z., Han, D. H., Xie, S., & Jin, J. (2025) · Aquaculture · doi:10.1016/j.aquaculture.2025.743432
Additional file 3 of Metabolic signatures of insulin resistance in non-diabetic individuals
Arjmand, B., Ebrahimi Fana, S., Ghasemi, E., Kazemi, A., Ghodssi-Ghassemabadi, R., Dehghanbanadaki, H., Najjar, N., Kakaei, A., Forouzanfar, K., Nasli‐Esfahani, E., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20625078
Additional file 1 of Metabolic signatures of insulin resistance in non-diabetic individuals
Arjmand, B., Ebrahimi Fana, S., Ghasemi, E., Kazemi, A., Ghodssi-Ghassemabadi, R., Dehghanbanadaki, H., Najjar, N., Kakaei, A., Forouzanfar, K., Nasli‐Esfahani, E., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20625072
Additional file 2 of Metabolic signatures of insulin resistance in non-diabetic individuals
Arjmand, B., Ebrahimi Fana, S., Ghasemi, E., Kazemi, A. S., Ghodssi-Ghassemabadi, R., Dehghanbanadaki, H., Najjar, N., Kakaei, A., Forouzanfar, K., Nasli‐Esfahani, E., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20625075
Implication of mitochondria endoplasmic-reticulum interactions in the control of hepatic metabolism
Theurey, P. (2015) · theses.fr (ABES) · doi:10.70675/c827066dz5c76z4f0azb465z409dc90bb0e5
Lv, C., Luo, N., Wei, C., Zhang, Q., Guo, K., Jiang, X., Cao, X., Maghsoudloo, M., El-Far, A., & Fu, J. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00923-x
Wong, A., Luo, W., Xuan, J., Gupta, H., Li, M., Natraj, A., Madullapalli, S., Tao, H., Wahng, C., Balan, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.23.727424
Mitochondrial ATP promotes T cell differentiation through chromatin accessibility
Ng, C., Fung, T. S., Li, D., Kropp, K. N., Patterson, L. F. S., Markovitz, A., Weinberg, D. N., Jones, O., Kim, J.-Y., Zhang, G., et al. (2026) · Cell · doi:10.1016/j.cell.2026.08.023 · Cited by 1
BindingDB Entry 50021338: Modulators for palmitoylation of proteins and small molecules.
BindingDB (2025) · UC San Diego · doi:10.7270/q2959p6h
Metadata
- Authors
- Conti, R., Mannucci, E., Pessotto, P., Tassoni, E., Carminati, P., Giannessi, F., & Arduini, A.
- Affiliations
- Sigma Tau (Italy) (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Paolo Carminati, sigma-tau s.p.a, Rome, Italy
- Corresponding author
- Conti, Roberto
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-01-21
- Volume
- 60
- Issue
- 2
- Pages
- 644-651
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3028366
- OpenAlex
- W1986038576
- Cited by
- 98
- References
- 46
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 7 · 2023: 8 · 2022: 10 · 2021: 6 · 2020: 4 · 2019: 9 · 2018: 7 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 3 · 2013: 4 · 2012: 5
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- carnitine palmitoyltransferase 1, gluconeogenesis, glucose homeostasis, antidiabetic drugs, insulin sensitivity, hepatic triglycerides, type 2 diabetes, db/db mice, high-fat diet, ketone bodies, insulin tolerance test, hyperinsulinemic-euglycemic clamp
- MeSH terms
- Analysis of Variance, Animals, Carnitine, Carnitine O-Palmitoyltransferase, Diabetes Mellitus, Type 2, Dietary Fats, Gluconeogenesis, Glucose, Heart, Homeostasis, Insulin Resistance, Liver, Male, Myocardium, Rats, Sprague-Dawley, Area Under Curve, Hepatocytes, PPAR alpha, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.